- Jiangsu Hengrui’s revenue for the first half of 2025 reached 15.76 billion yuan, aligning with the market estimate of 15.69 billion yuan.
- Net income reported by the company was 4.45 billion yuan.
- Research and Development (R&D) expenses totaled 3.23 billion yuan, which was below the estimated 3.49 billion yuan.
- Earnings per share (EPS) came to 70 RMB cents.
- Analysts’ recommendations include 30 buy ratings, 4 hold ratings, and 1 sell rating.
Jiangsu Hengrui Medicine on Smartkarma
Analysts on Smartkarma have been keeping a close eye on Jiangsu Hengrui Medicine. Tina Banerjee‘s research on ‘ADC Drug Approval Presents Long-Term Opportunity’ highlights the conditional approval received by Jiangsu Hengrui for Trastuzumab Rezetecan, with a 20% sales growth reported in 1Q25. The company’s focus on innovative drugs and licensing is set to further drive momentum, with expectations for potential FDA approval serving as a near-term stock trigger.
Xinyao (Criss) Wang‘s insights on ‘China Healthcare Weekly’ touch on the potential impact of Trump’s drug price reduction plans on China’s pharmaceutical assets, emphasizing that Hengrui’s IPO in Hong Kong has garnered interest despite fundamental concerns. Sumeet Singh and Brian Freitas also provide bullish perspectives on Jiangsu Hengrui Medicine, discussing the company’s recent H-share listings and potential index inclusions that could shape its future trajectory in the market.
A look at Jiangsu Hengrui Medicine Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 1 | |
| Growth | 4 | |
| Resilience | 5 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on Smartkarma Smart Scores, Jiangsu Hengrui Medicine shows a promising long-term outlook. The company fares well in Growth, Resilience, and Momentum, with scores of 4 and 5 indicating strong performance in these areas. This suggests that Jiangsu Hengrui Medicine has potential for sustainable growth and adaptability in the face of challenges.
While the Value and Dividend scores are not as high, with scores of 2 and 1 respectively, the company’s overall position seems positive. Jiangsu Hengrui Medicine‘s focus on developing, manufacturing, and marketing various medicines and medical packing materials positions it in key areas of the healthcare industry, providing a solid foundation for future success.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
